Compare Nakanishi, Inc. with Similar Stocks
Dashboard
1
Positive results in Jun 26
- NET PROFIT(HY) At JPY 8,144.52 MM has Grown at 130.85%
- RAW MATERIAL COST(Y) Fallen by -0.11% (YoY)
- CASH AND EQV(HY) Highest at JPY 117,594.57 MM
2
With ROE of 12.82%, it has a attractive valuation with a 2.38 Price to Book Value
3
Majority shareholders : FIIs
4
Company is among the highest 1% of companies rated by MarketsMojo across all 4,000 stocks
Stock DNA
Pharmaceuticals & Biotechnology
JPY 280,343 Million (Mid Cap)
19.00
NA
0.00%
-0.24
12.82%
2.41
Revenue and Profits:
Net Sales:
24,746 Million
(Quarterly Results - Jun 2026)
Net Profit:
4,164 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
1.24%
0%
1.24%
6 Months
6.69%
0%
6.69%
1 Year
45.86%
0%
45.86%
2 Years
21.67%
0%
21.67%
3 Years
-17.74%
0%
-17.74%
4 Years
7.95%
0%
7.95%
5 Years
18.65%
0%
18.65%
Nakanishi, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
18.07%
EBIT Growth (5y)
6.76%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
0.54
Tax Ratio
81.58%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.04%
ROCE (avg)
21.15%
ROE (avg)
10.82%
Valuation key factors
Factor
Value
P/E Ratio
19
Industry P/E
Price to Book Value
2.38
EV to EBIT
16.17
EV to EBITDA
11.85
EV to Capital Employed
2.82
EV to Sales
2.93
PEG Ratio
0.15
Dividend Yield
NA
ROCE (Latest)
17.42%
ROE (Latest)
12.82%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Bullish
Dow Theory
No Trend
Mildly Bullish
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Jun 2026
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.04%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'26 - QoQ
Jun'26
Mar'26
Change(%)
Net Sales
24,746.20
22,488.70
10.04%
Operating Profit (PBDIT) excl Other Income
6,893.50
5,876.20
17.31%
Interest
118.80
71.20
66.85%
Exceptional Items
0.00
0.00
Consolidate Net Profit
4,164.20
3,980.30
4.62%
Operating Profit Margin (Excl OI)
215.70%
207.90%
0.78%
USD in Million.
Net Sales
QoQ Growth in quarter ended Jun 2026 is 10.04% vs 0.28% in Mar 2026
Consolidated Net Profit
QoQ Growth in quarter ended Jun 2026 is 4.62% vs 146.39% in Mar 2026
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
81,179.10
77,041.40
5.37%
Operating Profit (PBDIT) excl Other Income
19,899.40
20,460.40
-2.74%
Interest
199.20
67.30
195.99%
Exceptional Items
-13,627.40
-3,464.50
-293.34%
Consolidate Net Profit
-2,398.20
8,578.80
-127.95%
Operating Profit Margin (Excl OI)
173.60%
189.50%
-1.59%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 5.37% vs 29.06% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -127.95% vs -62.38% in Dec 2024
About Nakanishi, Inc. 
Nakanishi, Inc.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available
Footer loading






